TO THE EDITOR
Patients with disseminated 'low-grade' or 'indolent' lymphoproliferative disorders such as follicular lymphoma and chronic lymphocytic leukaemia (CLL) remain incurable with currently available therapies, although temporary disease control can usually be obtained.
High-dose therapy with autologous stem cell rescue is an increasingly applied treatment for younger patients (o65 years). In patients with recurrent chemotherapy-sensitive low-grade non-Hodgkin's lymphoma (NHL), or CLL, high rates of complete remission and moderate rates of durable disease control can be attained.
For an autograft to be successful, a minimum number of stem cells must be obtained from a mobilization procedure, to ensure an acceptable rate of haemopoietic recovery and a low rate of graft failure. Patients with lymphoid malignancies, particularly those with 'low-grade' histology, have a higher rate of collection failure.
1 Many of these patients may have received multiple prior courses of potentially myelotoxic therapy. In a number of studies of this patient group, prior treatment with the purine analogue fludarabine has been associated with impaired mobilization. [2] [3] [4] [5] Ketterer et al 2 examined 200 patients with lymphoid malignancies and identified prior exposure to fludarabine as the most significant predictor of a sub-optimal stem cell collection (P ¼ 0.0008).
Given that fludarabine is a potent cytotoxic agent in both initial and salvage therapy of patients with lymphoproliferative disorders and is becoming more widely used in this setting, the problem of impaired stem cell mobilization may become an increasingly frequent clinical issue. Only one previous study 4 has specifically examined the factors contributing to poor stem cell yield in fludarabine-exposed patients, and was restricted to patients with CLL. We therefore analysed our own experience with peripheral blood stem cell (PBSC) mobilization in patients who had previously received fludarabine therapy, in order to identify factors associated with successful mobilization.
All patients from two centres who had received fludarabine at any time for treatment of an 'indolent' lymphoproliferative disorder, and subsequently had an attempt at stem cell mobilization between January 1996 and November 2002, were included in the study. Patients with follicular grade III or largecell lymphoma were excluded, but those with mantle cell lymphoma were included (n ¼ 2).
Data on a number of variables that may affect the ability to collect PBSC were collected. These included patient age, gender and ECOG performance status, histologic diagnosis, total dose of fludarabine received, response to fludarabine, time between the last dose of fludarabine and the mobilization procedure, and the nature of the fludarabine-containing regimen (fludarabine alone or combination therapy with other potentially myelotoxic agents). Data on prior radiotherapy were also collected, with radiation-related myelotoxicity considered possible when a significant proportion of bone marrow was included in the radiation field. Bone marrow reserve was indirectly assessed by bone marrow involvement and full blood count parameters at the time of mobilization. The impact of additional potentially myelotoxic chemotherapy apart from fludarabine was also considered, by allocating a 'toxicity score' for prior chemotherapy based on a published score. 6 Each drug given was allocated a number between 0 (nonmyelotoxic, eg prednisolone) and 4 (highly myelotoxic, eg melphalan), and this number was multiplied by the total number of drug cycles administered. One month of continuous chlorambucil was designated one 'cycle'. The 22 regimens for which the cycle number was unknown were considered to have had four cycles (the median number of cycles overall). Toxicity scores for all nonfludarabine chemotherapeutic agents were added to give a total score.
Peripheral blood (PB) CD34 þ count determined using threeparameter flow cytometry was used to determine the timing of commencement of stem cell harvesting. A threshold of 2 Â 10 6 /l CD34 þ cells was deemed adequate. PB CD34 þ count was performed on a daily basis until harvesting was complete. Daily leukaphereses were performed until a total of 42 Â 10 6 /kg CD34 þ cells were collected, or until a declining PB CD34 þ count indicated that further procedures were unlikely to be useful. For 12 of 54 mobilization attempts, the threshold PB CD34 þ count was not reached, and thus leukapheresis was never commenced. Some patients who had a suboptimal or unsuccessful first mobilization procedure went on to have additional further mobilization attempts. Patients from whom ultimately X2 Â 10 6 /kg CD34 þ cells were collected were considered to have had a successful mobilization overall.
We tested the significance of the association of individual factors with successful mobilization using the Fisher exact test for binomial variables, the exact version of the CochranArmitage test for trend for ordinal values and the w 2 test for contingency tables for nominal values. Multifactor analyses were carried out using exact logistic regression. As this was an exploratory study, and no previous literature was available to determine cutpoints for continuous variables, cutpoints were chosen to give three groups of similar sizes. These groups were assigned the values 1, 2 and 3, respectively, for testing the trends. In the multifactor analyses, age was studied as a continuous variable. Two-sided P-values have been reported throughout. No adjustment to the P-values has been made for multiple comparisons.
Overall, there were 41 eligible patients (Table 1) , utilizing a variety of mobilization regimens in 54 separate mobilization attempts. In nine cases, G-CSF was used either alone (eight cases) or in combination with stem cell factor (one case), at total doses ranging from 5 mg/kg/day to 12 mg/kg twice daily. In all, 39 mobilization attempts used cyclophosphamide as a single agent plus G-CSF (5-14 mg/kg daily), either alone (35 cases), or in combination with stem cell factor (four cases), with cyclophosphamide given at a dose of 1.5 g/m 2 in 32 cases, 2 g/m 2 in four cases and at 4 g/m 2 in three cases. A combination of G-CSF and other chemotherapy regimens was utilized in six mobilization attempts (fludarabine/mitoxantrone in three cases, fludarabine/cyclophosphamide in one case, ifosfamide/etoposide/ rituximab in one case and etoposide/carboplatin/ifosfamide in one case).
The first mobilization attempt was successful in 14 patients (34%, 95% CI 21-50%), suboptimal in 18 (44%, 95% CI 28-60%) and unsuccessful in the remaining nine (22%, 95% CI 12-37%). In the 32 patients in whom apheresis was commenced, the total number of CD34 þ cells/kg collected ranged from 0.09 to 26 Â 10 6 (median 1.7). In all, 30 patients (73%) had one mobilization attempt, nine (22%) had two attempts and two (5%) had three attempts. Including the collected products from all attempts, the overall mobilizations were successful in 19 patients (46%, 95% CI 31-63%), suboptimal in 14 (34%, 95% CI 21-50%) and unsuccessful in eight (20%, 95% CI 9-34%). Of the 19 successful mobilizations, 14 were successful following the first, three were successful following the second and two were successful following the third mobilization.
Eight patients had no CD34 þ cells collected. For the remaining 33 patients, the CD34 þ cells were infused for 11 patients, were not cryopreserved for one patient who only had 0.09 Â 10 6 cells collected, and, at the time of analysis, were in storage for the remaining 21 patients. Of the 11 patients with cells infused, two had sub-optimal total collections and had their cells infused in combination with a bone marrow harvest. G-CSF support was routinely used post-transplant. The median time to neutrophil recovery (40.5 Â 10 9 /l) was 10 days (range 10-15 days), and the median time to platelet recovery (420 Â 10 9 /l) was 15 days (range 11-117 days). Without adjusting for multiple comparisons, three factors were associated with mobilization success at a screening significance level of 0.05 (Table 2) : age, haemoglobin level and bone marrow involvement.
The probability of success decreased with increasing age (Figure 1) . The age at the time of the first mobilization attempt ranged from 34 to 65 years (median 51 years). Patients aged 50 years or over had only a 17% chance of successful mobilization at the first attempt (P ¼ 0.0079), and only 33% were ultimately successful (P ¼ 0.062). None of the six patients over the age of 60 years mobilized successfully. In contrast, approximately twothirds of the younger patients (o50 years of age) ultimately had sufficient stem cells collected. Age has not been found to be a significant predictor of collection success in previous studies of non-fludarabine-exposed patients. 1-3,7 However, it is possible that older patients are more susceptible to the stem cell toxic effects of fludarabine, due to impaired stem cell reserve, or differences in fludarabine drug metabolism.
The presence of anaemia prior to mobilization was also associated with a poor collection, with no patients with a low haemoglobin achieving a successful initial mobilization (P ¼ 0.019). However, low white cell or platelet counts were not predictive for poor mobilization, although a nonsignificant trend for thrombocytopenia to predict a poor initial count was observed (P ¼ 0.099). The negative influence of anaemia on mobilization success supports the hypothesis that cytopenias can in part reflect damage to stem cells. Although in this study thrombocytopenia did not significantly predict for a poor collection, this may be due to small patient numbers as the Ketterer study 2 did demonstrate more frequent failed collections in thrombocytopenic patients. Alternatively, thrombocytopenia may be caused by a number of other mechanisms in this patient cohort (autoimmune, hypersplenism).
The involvement of the bone marrow with disease at the time of mobilization was surprisingly associated with a greater likelihood of successful collection, with 68% of these patients ultimately achieving an adequate stem cell collection (P ¼ 0.010). This is likely to be a spurious result. The conclusion appears counterintuitive, and is not consistent with the results of Data for nine patients unknown. c Data for one patient unknown. CT -chemotherapy; G-CSF -granulocyte colony stimulating factor; LLN -lower limit of normal range.
other investigators, who have identified bone marrow disease as a predictor of mobilization failure. 2, 8 One possible explanation is that this study only noted the presence or absence of bone marrow disease, and a small number of tumour cells in the marrow may not have any effect on stem cell function. In contrast, extensive involvement with disease may be more likely to predict stem cell toxicity and hence mobilization failure; a larger patient cohort quantifying degrees of marrow infiltration would assist in determining this.
In multifactor analyses, age and bone marrow involvement were both significant predictors of ultimately achieving an adequate stem cell collection (P ¼ 0.025 and 0.0055, respectively); however, age, anaemia and bone marrow involvement were not jointly significant predictors of achieving a successful initial mobilization (P ¼ 0.082, 0.25 and 0.10, respectively) for the 35 patients who had the relevant data available. Note that for this subset of patients, age and anaemia were significant in unifactor analyses (P ¼ 0.023 and 0.032, respectively) but marrow involvement was not significant (P ¼ 0.075). In a multifactor analysis studying age and anaemia in the 40 patients with both factors recorded, age was a significant predictor of a successful initial mobilization (P ¼ 0.022) but anaemia was not (P ¼ 0.13). More data are needed to be confident of the joint significance of these factors.
Unsurprisingly, the peripheral blood CD34 þ count on the day of apheresis was highly significant in predicting an adequate CD34 þ yield (Table 3 ). In contrast to previous studies, we have not demonstrated any relationship between poor stem cell collections and the intensity of previous chemotherapy as measured by the toxicity score, or the duration of therapy. The response to fludarabine does not appear to be a predictor of the success of mobilization. In addition, the combination of fludarabine with other chemotherapeutic agents does not seem to be more stem cell toxic than fludarabine alone. Previous reports describe the number of previous chemotherapy courses, 2, 4 the numbers of chemotherapy cycles, 7, 8 extensive exposure to myelotoxic chemotherapy 2, 3, 6 and a shorter interval between chemotherapy and mobilization, implying the possibility of short-term reversible stem cell toxicity 1,4 as predictive factors for poor collections. The absence of such predictive factors in our study may reflect the fact that although extensive chemotherapy may theoretically increase the risk of stem cell damage, the contribution from these agents may not necessarily be significant in the context of fludarabine pre-treatment.
The likelihood of successful initial PBSC mobilizations in this study was similar to previously published figures for patients with indolent lymphoproliferative disorders. Our CLL cohort had a 43% success rate in comparison to 54% in another fludarabineexposed group. 4 The low-grade lymphoma cohort achieved 42 Â 10 6 CD34 þ cells/kg in 33% of cases, compared with a 28% success rate in a study by Perry et al.
1 Despite the reported poor stem cell yields in fludarabine-exposed patients, it is clearly still feasible to attempt stem cell collection in these patients.
In conclusion, in this patient cohort, only younger age (o50 years) is clearly associated with an increased likelihood of successful stem cell mobilization. In addition, no anaemic patients had a successful mobilization procedure. On the basis of this study, it may be appropriate to consider earlier stem cell harvesting in fludarabine-exposed patients with indolent lymphoproliferative disorders, both in older patients and in those predicted by pre-existing cytopenias to have poorer stem cell reserve, to improve the chances of a successful mobilization. Given that we found no link between the type of mobilization regimen and success of harvesting, new mobilization regimens are clearly essential in this cohort. We are currently investigating the efficacy of stem cell factor and highdose twice-daily G-CSF for stem cell mobilization in such patients. 1 Though the ineffective hematopoiesis may be due to excessive apoptosis in MDS, 2 the precise mechanism is unknown. Chemokines are small cytokines that are important as intermediates in the inflammatory response, and are regulatory proteins for the recruitment and trafficking of leukocytes. 3 Recently, stromal cell-derived factor-1 (SDF-1) was identified as the predominant chemotactic factor produced by bone marrow cells. 4 The SDF-1 and its receptor CXCR4 are involved in the mobilizing and trafficking of hematopoietic progenitor cells. 5 SDF-1 also enhances survival/antiapoptosis of hematopoietic progenitor cells, in vitro as well as in vivo, 6 suggesting that the SDF-1/CXCR4 system plays an important role in hematopoietic cell regulation. Therefore, we investigated the The apoptosis of CD34 + progenitor cells was qualified by the Annexin V method. CXCR4 expression in mean fluorescence intensities (MFI) on CD34 + progenitor cells was given after correction with reference to the mouse IgG control. SDF-1-induced chemotaxis was expressed as % input cells. SDF-1 concentration in BM plasma was measured by ELISA.
